Clinical Trial

A Clinical Study of SHR-5421 in Patients With Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-31
Trial Details
NCT Number NCT07652281
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Multiple Myeloma
Enrollment 97 participants
Start Date 2026-07-23
Primary Completion 2028-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-30